| 产品描述: | PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3 nM and 60.8 nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research. |
| 靶点: |
PLK1:0.3 nM (IC50); BRD4:60.8 nM (IC50) |
| 体外研究: |
PLK1/BRD4-IN-5 在 Sprague-Dawley 大鼠体内的药动学参数 |
| 体内研究: |
PLK1/BRD4-IN-5 (Compound SC10) 对三种肿瘤细胞系都具有显著的抗增殖活性 (MDA-MB-231 IC50 = 17.3 nM, MDA-MB-361 IC50 = 8.4 nM, MV4-11 IC50 = 5.4 nM)。 |
| 参考文献: |
1. Liu J, et al. Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer. Bioorg Med Chem. 2024;101:117 |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.734 ml |
8.67 ml |
17.339 ml |
| 5 mM |
0.347 ml |
1.734 ml |
3.468 ml |
| 10 mM |
0.173 ml |
0.867 ml |
1.734 ml |
| 50 mM |
0.035 ml |
0.173 ml |
0.347 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |